Cyplasin Biomedical Ltd Announces Japanese Patent for its Antitumor Protein
"It is gratifying to receive the approval of our patent application since it was obtained after many years of careful in-depth-analysis by the Japanese Patent Office. It describes our intellectual property for the cytotoxic Cyplasin to be used as an anticancer substance, especially valuable in one of the most important economies worldwide. Together with corresponding US and European patents Cyplasin Biomedical Ltd relies now on a solid intellectual property portfolio allowing it to proceed successfully in the rapid development of Cyplasin," said Professor Christian Petzelt, Chief Scientific Officer of Cyplasin Biomedical Ltd.
Cyplasin-SC TM has demonstrated a selective ability to rapidly kill certain types of cancer cells while leaving normal non-cancerous cells untouched. Cyplasin-SC TM is a protein originally discovered and isolated by Professor Petzelt from a marine organism, the sea hare (Aplysia punctata). The protein can now be manufactured as a recombinant protein which allows the company to develop the protein as an anti-cancer therapeutic product. United States and European Patents have been issued to the Company covering the Cyplasin-SC TM protein.
Most read news
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.